Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Public biotech 2010—the numbers

The biotech sector has bounced back, though the figures can be somewhat misleading.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Global biotech industry financing.
Figure 2: Global biotech IPOs.
Figure 3: Public biotech barometers.
Figure 4: Public biotech companies by geographical location.


The authors would like to thank C. Dokomajilar, Senior Biotech Analyst, Deloitte Recap and J. Loughmiller, Managing Director, ARC Consulting, Walnut Creek, CA, USA for their help in crafting this article.

Author information

Authors and Affiliations


Supplementary information

Supplementary Text and Tables

Supplementary Table 1 (XLS 144 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Huggett, B., Hodgson, J. & Lähteenmäki, R. Public biotech 2010—the numbers. Nat Biotechnol 29, 585–591 (2011).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing